Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.66 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALAD | P13716 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15988671 | 0.83 | GSK3B (0.70) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL15282434 | 0.81 | GSK3B (0.68) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL27794744 | 0.81 | ALAD (0.66) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL23617480 | 0.80 | GSK3B (0.61) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL6784161 | 0.79 | GSK3B (1.00) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL3752532 | 0.79 | DAO (0.61) | GSK3BCES2CES1SMN1; SMN2MAPT | |
| SCHEMBL10513671 | 0.79 | MAPT (0.47) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL15483705 | 0.79 | GSK3B (0.59) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL12261095 | 0.78 | GSK3B (0.41) | GSK3BCES2CES1ALDH1A1LMNA | |
| SCHEMBL13267640 | 0.78 | MAPT (0.50) | GSK3BCES2CES1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117864-B2 | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20180036300-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-08 | — | — | US | disclosed |
| EP-3271334-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146602-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | WO | disclosed |
| US-20150184307-A1 | SILVER ELECTROPLATING SOLUTION | DAIWA FINE CHEMICALS CO., LTD. (LABORATORY) (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2881497-A1 | ELECTROSILVER PLATING FLUID | Daiwa Fine Chemicals Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| CN-104185635-A | Tetrahydropyrrolothiazine compounds | LILLY CO ELI | 2014-12-03 | — | — | CN | disclosed |
| CN-101605775-B | Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same | GENFIT FR | 2014-11-12 | — | — | CN | disclosed |
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102762551-A | Thienylpyri (mi) dinylpyrazoles and their use for controlling phytopathogenic fungi | BAYER CROPSCIENCE AG | 2012-10-31 | — | — | CN | disclosed |
| US-6706725-B1 | BIAROMATIC COMPOUNDS WHICH ARE VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-03-16 | — | — | US | disclosed |
| CN-1423645-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2003-06-11 | — | — | CN | disclosed |
| EP-1235777-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2002-09-04 | — | — | EP | disclosed |
| EP-1235824-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001038320-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001038303-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-05-31 | — | — | WO | disclosed |
| EP-0777655-B1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | ABBOTT LAB (US) | 2001-01-10 | — | — | EP | disclosed |
| US-5659037-A | FROM VERATROL DERIVATIVE CHIRAL STARTING MATERIAL USING SERIES OF CHIRAL-PRESERVING REACTIONS | ABBOTT LABORATORIES (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0777655-A1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | Abbott Laboratories (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006085-A1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117864-B2 | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | AADAC, BRD4, GOT2 | GSK3B 3321/4885CES2 131/4885CES1 286/4885 |
| US-20180036300-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | AADAC, BRD4, GOT2 | GSK3B 3321/4885CES2 131/4885CES1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.